The μ-bcr breakpoint connects exon 19 of BCR with ABL giving rise to the e19a2 transcript corresponding to the p230 fusion protein (micro-BCR breakpoint) which is rarely seen in chronic myeloid leukemia (CML) patients. Here we report three patients with p230 fusion protein presenting with different clinical presentations and diagnosed as CML-CP. These patients received Imatinib (tyrosine kinase inhibitor-TKI) and are still in remission.
Keywords: Chronic myeloid leukemia; Major molecular response (MMR); RQ-PCR; RT-PCR; e19a2 BCR–ABL fusion transcript.
Copyright © 2016 Elsevier Inc. All rights reserved.